Developer docs
API playgroundTry for free, no card

Search company profiles

NXTSTIM

Full company profile

uuid000pfjp

Namestring
NXTSTIM
Legal namestring
NXTSTIM, Inc.
Websiteurl
nxtstim.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

NXTSTIM is a San Diego-based medical device company founded in 2020 by Dr. Krishnan Chakravarthy that develops and commercializes EcoAI, an FDA 510(k)-cleared, AI-powered, non-invasive neuromodulation device for chronic pain management. The product is built around proprietary SmartWave waveform technology delivered through a small, wireless, rechargeable wearable paired with a mobile application and a clinician-facing dashboard. Dual sensors capture neural and EMG responses, and an AI module closes the loop by adjusting stimulation parameters in real time, with a published 75% accuracy for pain-response prediction in real-world studies. The system is designed for home use while feeding Remote Therapeutic Monitoring (RTM) data back to prescribing clinicians under HIPAA/HITECH compliance and a Business Associate Agreement framework.

The business sells EcoAI exclusively through a prescription-only channel: licensed partner clinics, a growing national Centers of Excellence network, and an internal in-house LPN/LVN care management team that handles onboarding, training, patient support, and RTM documentation. Revenue is generated through three streams: hardware sales of the EcoAI device and recurring gel-pad consumables, RTM services billed by clinics via CMS-aligned CPT codes (98975/98977/98980/98981), and professional services supporting clinic onboarding and billing. Reimbursement is enabled across Medicare, Medicaid (state-dependent), and major commercial payors including UnitedHealthcare. The go-to-market combines enterprise field sales into physician practices with patient-facing demand generation through the website, app stores, podcasts, conferences, and peer-reviewed publications such as the Journal of Pain Research.

NXTSTIM has scaled from its 2020 founding through an NIH SBIR Phase 1 grant in 2021 to 1,000+ patients by 2023 and 3,000+ cumulative patients in 2025, with a stated 180% growth rate in 2025. The installed base is supported by 24 months of real-world outcome data showing a 92% compliance rate at 18+ months, a 2.5-point average reduction on the numeric pain rating scale, and zero reported device-related adverse events. The company is privately held and founder-controlled, headquartered in San Diego, with an operating footprint primarily in the U.S. and selected international advocacy (e.g., AZ Delta Hospital in Belgium) but no disclosed venture funding to date.

Short descriptiontext

NXTSTIM is a San Diego-based medical device company that develops EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation device with Remote Therapeutic Monitoring for chronic pain management, sold through licensed partner clinics and a growing Centers of Excellence network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation devices, pain management solutions, remote therapeutic monitoring, neurostimulation technology, wearable medical devices
Industry4 codes
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALABAK
Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALADAD
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Pain Management Devices
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1EcoAI Device Sales
TypeHardware Sales
Description

EcoAI device is sold to patients through licensed partner clinics. The device is a one-time purchase that includes reusable hardware with rechargeable battery. Pricing is determined in partnership with insurance coverage.

nxtstim.com
2Gel Pads (Consumables)
TypeHardware Sales
Description

Disposable gel pads are sold as consumable supplies. Available in multiple sizes for optimal skin contact. Regular reordering required for ongoing therapy.

nxtstim.com
3Remote Therapeutic Monitoring (RTM) Services
TypeManaged Services
Description

Clinics bill for RTM services using CPT codes 98975-98981. NXTSTIM provides documentation tools and billing support. CMS reimbursement rates: $19.73 (setup), $43.02/month (device supply), $50.14/month (monitoring), $39.14/month (add-on monitoring).

nxtstim.com
4Professional Services & Support
TypeProfessional Services
Description

NXTSTIM provides onboarding, staff training, patient support, and RTM assistance as part of the clinic partnership. Optional billing support includes review of RTM data and preparation of billing reports.

nxtstim.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details4 tiers
1CPT 98975 - Device Setup (One-time)
ModelOtherBilling cadencePay-as-you-go
Notes

$19.73 - One-time setup of the device, along with patient education and training to ensure proper use.

nxtstim.com
2CPT 98977 - Device Supply (Monthly)
ModelOtherBilling cadenceMonthly
Notes

$43.02 per 30 days - Supply for musculoskeletal system monitoring, used with EcoAI device.

nxtstim.com
3CPT 98980 - RTM Monitoring & Interaction (Monthly)
ModelOtherBilling cadenceMonthly
Notes

$50.14/month - Treatment management with one interactive communication between clinician and patient.

nxtstim.com
4CPT 98981 - RTM Add-on Monitoring (Monthly)
ModelOtherBilling cadenceMonthly
Notes

$39.14/month - Each additional 20 minutes of treatment management beyond the initial 20 minutes covered by CPT 98980.

nxtstim.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1EcoAI
Description

FDA-approved, AI-powered, non-invasive neuromodulation device with Remote Therapeutic Monitoring (RTM) for pain relief. Features SmartWave technology that blocks pain signals and activates natural pain-blocking systems.

nxtstim.com
+1 more record
Core offering1 text field

NXTSTIM designs and manufactures EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation wearable device for chronic pain management, paired with a clinician-facing Remote Therapeutic Monitoring (RTM) platform. The product is prescription-only and sold through a network of licensed partner clinics (Centers of Excellence), with companion mobile apps (iOS/Android), disposable gel pad consumables, and cloud-based clinician dashboards for monitoring and CMS-aligned billing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 92% patient compliance rate at 18+ months
+6 more records
Product overview1 text field

NXTSTIM offers a unified ecosystem centered on EcoAI, an FDA-approved AI-powered neurostimulation device for chronic pain management. The ecosystem includes the EcoAI device with proprietary SmartWave technology, NXTSTIM mobile app (iOS/Android) for device control and therapy tracking, EcoAI Gel Pads as disposable accessories, a Clinician Dashboard for healthcare provider oversight, and Remote Therapeutic Monitoring (RTM) capabilities. The system provides a closed-loop pain relief solution where EcoAI adapts stimulation in real-time based on neural response monitoring, with all data syncing to both patient app and clinician dashboard for continuous care optimization.

Product and service5 records
1EcoAI Neuromodulation Device
CategoryMedical Device
Description

FDA-cleared, wireless, wearable neuromodulation device that uses proprietary SmartWave technology combined with AI-driven adaptive therapy to deliver non-invasive, drug-free pain relief for chronic pain conditions (neck, back, shoulders, knees, muscle/nerve-related). Sold by prescription through partner clinics.

2NXTSTIM Mobile App
CategoryMobile Application
Description

Companion mobile application for iOS and Android that pairs with the EcoAI device, allows patients to select therapy modes (Relax, Strengthen, Relieve), tracks sessions in a treatment diary, delivers personalized recommendations, and connects to the care team for remote adjustments.

3EcoAI Gel Pads
CategoryDevice Consumables
Description

Disposable electrode pads sold in multiple sizes to ensure optimal skin contact for the EcoAI device across different body regions. Consumable that requires regular reordering for ongoing therapy.

4Clinician Dashboard / Provider Portal
CategoryClinician Software Platform
Description

Web-based portal for healthcare providers that surfaces real-time adherence, therapy sessions, NRS pain scores, and pain trends per patient, and supports RTM billing with automated superbills and compliance tracking aligned with CMS CPT codes 98975-98981.

5Care Coordination Program
CategoryCare Management Services
Description

Service program in which NXTSTIM's in-house LPN and LVN care team provides ongoing monitoring, personalized check-ins, patient education, and care coordination for chronic pain patients using EcoAI.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Journal of Pain Research
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Peer-reviewed publication partnership. A narrative review was published examining how EcoAI integrates remote patient monitoring with AI-powered neuromodulation to deliver personalized, adaptive pain treatment.

nxtstim.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Jaspal Ricky Singh from Weill Cornell Medicine is featured as an EcoAI advocate, providing testimonial on the device's ability to shape long-term patient care with non-pharmacologic pain therapy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Bart Billet, MD Anesthesiologist at AZ Delta Hospital in Roeselare, Belgium, provides testimonial on EcoAI as an innovative, affordable, and non-invasive pain therapy option.

4ASPN (American Society of Pain and Neuroscience)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

NXTSTIM exhibited at ASPN 2025 conference presenting real-world data from 1,200 EcoAI users showing lasting pain relief, strong adherence, and predictive insights.

nxtstim.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Kip Theno and Dr. Chakravarthy appeared on the SamaCare podcast discussing EcoAI and pain management innovation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Boston Scientific markets the WaveWriter Alpha and Precision spinal cord stimulation systems. It is a broad incumbent in chronic-pain neuromodulation and a natural strategic acquirer of emerging neuromodulation assets.

TypeEmerging player
Description

SPR Therapeutics makes the Sprint peripheral nerve stimulation system for acute and chronic pain. It is an emerging neuromodulation peer that, like NXTSTIM, targets non-opioid pain pathways but with a minimally invasive approach.

TypeBroad incumbent
Description

Abbott offers the Proclaim DRG and Infinity spinal cord stimulation systems for chronic pain. It is a broad incumbent in implantable neuromodulation whose adjacent capabilities and physician relationships compete for chronic-pain wallet share.

4Omron Healthcare
TypeBroad incumbent
Description

Omron sells consumer and clinical TENS/EMS devices (e.g., Avail) for pain management. It is a broad incumbent that competes with EcoAI on the lower-cost consumer TENS side and could move up-market.

TypeBroad incumbent
Description

Medtronic is a global medtech incumbent with a large neuromodulation portfolio (spinal cord stimulation, deep brain stimulation, targeted drug delivery). It is a broad incumbent whose scale and R&D could pressure NXTSTIM in adjacent indications.

TypeDirect peer
Description

electroCore makes gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine and cluster headache. It is a direct non-invasive neuromodulation peer with a similar FDA-cleared prescription hardware + app model.

TypeDirect peer
Description

NeuroMetrix makes Quell, an FDA-cleared wearable TENS device for chronic pain. It is the most direct competitor to NXTSTIM's EcoAI in the over-the-counter / prescription neuromodulation category for chronic musculoskeletal pain.

TypeEmerging player
Description

Hinge Health is a digital musculoskeletal care platform combining exercise therapy, coaching, and wearable sensors. It is an emerging player in the chronic-pain management space that overlaps with NXTSTIM on the digital-care and RTM delivery model.

TypeEmerging player
Description

Cala Health makes Cala Trio, a wearable TENS device for essential tremor. It is an emerging non-invasive neuromodulation peer using a similar prescription-wearable + app + clinician oversight model, focused on a different indication.

10Axonics
TypeBroad incumbent
Description

Axonics makes sacral and tibial neuromodulation systems for incontinence and overactive bladder. It is a broad incumbent in non-opioid neuromodulation with a similar miniaturized, patient-friendly device + clinician-monitor model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NXTSTIM

Neuromodulation Pain Management Devicesnxtstim.com

NXTSTIM is a San Diego-based medical device company that develops EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation device with Remote Therapeutic Monitoring for chronic pain management, sold through licensed partner clinics and a growing Centers of Excellence network.

What NXTSTIM does

NXTSTIM is a San Diego-based medical device company founded in 2020 by Dr. Krishnan Chakravarthy that develops and commercializes EcoAI, an FDA 510(k)-cleared, AI-powered, non-invasive neuromodulation device for chronic pain management. The product is built around proprietary SmartWave waveform technology delivered through a small, wireless, rechargeable wearable paired with a mobile application and a clinician-facing dashboard. Dual sensors capture neural and EMG responses, and an AI module closes the loop by adjusting stimulation parameters in real time, with a published 75% accuracy for pain-response prediction in real-world studies. The system is designed for home use while feeding Remote Therapeutic Monitoring (RTM) data back to prescribing clinicians under HIPAA/HITECH compliance and a Business Associate Agreement framework.

The business sells EcoAI exclusively through a prescription-only channel: licensed partner clinics, a growing national Centers of Excellence network, and an internal in-house LPN/LVN care management team that handles onboarding, training, patient support, and RTM documentation. Revenue is generated through three streams: hardware sales of the EcoAI device and recurring gel-pad consumables, RTM services billed by clinics via CMS-aligned CPT codes (98975/98977/98980/98981), and professional services supporting clinic onboarding and billing. Reimbursement is enabled across Medicare, Medicaid (state-dependent), and major commercial payors including UnitedHealthcare. The go-to-market combines enterprise field sales into physician practices with patient-facing demand generation through the website, app stores, podcasts, conferences, and peer-reviewed publications such as the Journal of Pain Research.

NXTSTIM has scaled from its 2020 founding through an NIH SBIR Phase 1 grant in 2021 to 1,000+ patients by 2023 and 3,000+ cumulative patients in 2025, with a stated 180% growth rate in 2025. The installed base is supported by 24 months of real-world outcome data showing a 92% compliance rate at 18+ months, a 2.5-point average reduction on the numeric pain rating scale, and zero reported device-related adverse events. The company is privately held and founder-controlled, headquartered in San Diego, with an operating footprint primarily in the U.S. and selected international advocacy (e.g., AZ Delta Hospital in Belgium) but no disclosed venture funding to date.

NXTSTIM firmographics

Firmographics
Name
NXTSTIM
Legal name
NXTSTIM, Inc.
Website
https://nxtstim.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
NXTSTIM is a San Diego-based medical device company that develops EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation device with Remote Therapeutic Monitoring for chronic pain management, sold through licensed partner clinics and a growing Centers of Excellence network.
Ownership category
akta.pro rank

NXTSTIM industry classification

Industry
Product category
Neuromodulation Pain Management Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALABAK
Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALADAD
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms

Keywords

  • Neuromodulation devices
  • Pain management solutions
  • Remote therapeutic monitoring
  • Neurostimulation technology
  • Wearable medical devices

Where NXTSTIM is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NXTSTIM business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. EcoAI Device Sales: EcoAI device is sold to patients through licensed partner clinics. The device is a one-time purchase that includes reusable hardware with rechargeable battery. Pricing is determined in partnership with insurance coverage.
  2. Gel Pads (Consumables): Disposable gel pads are sold as consumable supplies. Available in multiple sizes for optimal skin contact. Regular reordering required for ongoing therapy.
  3. Remote Therapeutic Monitoring (RTM) Services: Clinics bill for RTM services using CPT codes 98975-98981. NXTSTIM provides documentation tools and billing support. CMS reimbursement rates: $19.73 (setup), $43.02/month (device supply), $50.14/month (monitoring), $39.14/month (add-on monitoring).
  4. Professional Services & Support: NXTSTIM provides onboarding, staff training, patient support, and RTM assistance as part of the clinic partnership. Optional billing support includes review of RTM data and preparation of billing reports.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCPT 98975 - Device Setup (One-time)
OtherMonthlyCPT 98977 - Device Supply (Monthly)
OtherMonthlyCPT 98980 - RTM Monitoring & Interaction (Monthly)
OtherMonthlyCPT 98981 - RTM Add-on Monitoring (Monthly)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

NXTSTIM product offering

Product offering

Core offering

NXTSTIM designs and manufactures EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation wearable device for chronic pain management, paired with a clinician-facing Remote Therapeutic Monitoring (RTM) platform. The product is prescription-only and sold through a network of licensed partner clinics (Centers of Excellence), with companion mobile apps (iOS/Android), disposable gel pad consumables, and cloud-based clinician dashboards for monitoring and CMS-aligned billing.

Product overview

NXTSTIM offers a unified ecosystem centered on EcoAI, an FDA-approved AI-powered neurostimulation device for chronic pain management. The ecosystem includes the EcoAI device with proprietary SmartWave technology, NXTSTIM mobile app (iOS/Android) for device control and therapy tracking, EcoAI Gel Pads as disposable accessories, a Clinician Dashboard for healthcare provider oversight, and Remote Therapeutic Monitoring (RTM) capabilities. The system provides a closed-loop pain relief solution where EcoAI adapts stimulation in real-time based on neural response monitoring, with all data syncing to both patient app and clinician dashboard for continuous care optimization.

Differentiator

Problem solved

Functional benefit

Brands

  • EcoAI: FDA-approved, AI-powered, non-invasive neuromodulation device with Remote Therapeutic Monitoring (RTM) for pain relief. Features SmartWave technology that blocks pain signals and activates natural pain-blocking systems.
  • SmartWave

Products and services

  • EcoAI Neuromodulation Device FDA-cleared, wireless, wearable neuromodulation device that uses proprietary SmartWave technology combined with AI-driven adaptive therapy to deliver non-invasive, drug-free pain relief for chronic pain conditions (neck, back, shoulders, knees, muscle/nerve-related). Sold by prescription through partner clinics.
  • NXTSTIM Mobile App Companion mobile application for iOS and Android that pairs with the EcoAI device, allows patients to select therapy modes (Relax, Strengthen, Relieve), tracks sessions in a treatment diary, delivers personalized recommendations, and connects to the care team for remote adjustments.
  • EcoAI Gel Pads Disposable electrode pads sold in multiple sizes to ensure optimal skin contact for the EcoAI device across different body regions. Consumable that requires regular reordering for ongoing therapy.
  • Clinician Dashboard / Provider Portal Web-based portal for healthcare providers that surfaces real-time adherence, therapy sessions, NRS pain scores, and pain trends per patient, and supports RTM billing with automated superbills and compliance tracking aligned with CMS CPT codes 98975-98981.
  • Care Coordination Program Service program in which NXTSTIM's in-house LPN and LVN care team provides ongoing monitoring, personalized check-ins, patient education, and care coordination for chronic pain patients using EcoAI.

Quantifiable outcome

  • 92% patient compliance rate at 18+ months
  • +6 more outcomes

Companies that use NXTSTIM

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

NXTSTIM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

NXTSTIM partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Journal of Pain ResearchcoreStrategic or Co-development PartnerPeer-reviewed publication partnership. A narrative review was published examining how EcoAI integrates remote patient monitoring with AI-powered neuromodulation to deliver personalized, adaptive pain treatment.
  • Weill Cornell MedicineminorStrategic or Co-development PartnerDr. Jaspal Ricky Singh from Weill Cornell Medicine is featured as an EcoAI advocate, providing testimonial on the device's ability to shape long-term patient care with non-pharmacologic pain therapy.
  • AZ Delta Hospital (Belgium)minorStrategic or Co-development PartnerDr. Bart Billet, MD Anesthesiologist at AZ Delta Hospital in Roeselare, Belgium, provides testimonial on EcoAI as an innovative, affordable, and non-invasive pain therapy option.
  • ASPN (American Society of Pain and Neuroscience)minorStrategic or Co-development PartnerNXTSTIM exhibited at ASPN 2025 conference presenting real-world data from 1,200 EcoAI users showing lasting pain relief, strong adherence, and predictive insights.
  • SamaCareminorGTM or Marketing PartnerKip Theno and Dr. Chakravarthy appeared on the SamaCare podcast discussing EcoAI and pain management innovation.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

NXTSTIM competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Boston Scientific markets the WaveWriter Alpha and Precision spinal cord stimulation systems. It is a broad incumbent in chronic-pain neuromodulation and a natural strategic acquirer of emerging neuromodulation assets.
  • Abbott: Abbott offers the Proclaim DRG and Infinity spinal cord stimulation systems for chronic pain. It is a broad incumbent in implantable neuromodulation whose adjacent capabilities and physician relationships compete for chronic-pain wallet share.
  • Omron Healthcare: Omron sells consumer and clinical TENS/EMS devices (e.g., Avail) for pain management. It is a broad incumbent that competes with EcoAI on the lower-cost consumer TENS side and could move up-market.
  • Medtronic: Medtronic is a global medtech incumbent with a large neuromodulation portfolio (spinal cord stimulation, deep brain stimulation, targeted drug delivery). It is a broad incumbent whose scale and R&D could pressure NXTSTIM in adjacent indications.
  • Axonics: Axonics makes sacral and tibial neuromodulation systems for incontinence and overactive bladder. It is a broad incumbent in non-opioid neuromodulation with a similar miniaturized, patient-friendly device + clinician-monitor model.

Emerging players

  • SPR Therapeutics: SPR Therapeutics makes the Sprint peripheral nerve stimulation system for acute and chronic pain. It is an emerging neuromodulation peer that, like NXTSTIM, targets non-opioid pain pathways but with a minimally invasive approach.
  • Hinge Health: Hinge Health is a digital musculoskeletal care platform combining exercise therapy, coaching, and wearable sensors. It is an emerging player in the chronic-pain management space that overlaps with NXTSTIM on the digital-care and RTM delivery model.
  • Cala Health: Cala Health makes Cala Trio, a wearable TENS device for essential tremor. It is an emerging non-invasive neuromodulation peer using a similar prescription-wearable + app + clinician oversight model, focused on a different indication.

Direct peers

  • electroCore: electroCore makes gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine and cluster headache. It is a direct non-invasive neuromodulation peer with a similar FDA-cleared prescription hardware + app model.
  • NeuroMetrix: NeuroMetrix makes Quell, an FDA-cleared wearable TENS device for chronic pain. It is the most direct competitor to NXTSTIM's EcoAI in the over-the-counter / prescription neuromodulation category for chronic musculoskeletal pain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

NXTSTIM social profiles

Digital presence

NXTSTIM compliance and trust

Trust signal

Compliance5 records

NXTSTIM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NXTSTIM leadership team

Management profile

Number of profiles

Profiles8 records

NXTSTIM funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NXTSTIM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NXTSTIM

What does NXTSTIM do?

NXTSTIM designs and manufactures EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation wearable device for chronic pain management, paired with a clinician-facing Remote Therapeutic Monitoring (RTM) platform. The product is prescription-only and sold through a network of licensed partner clinics (Centers of Excellence), with companion mobile apps (iOS/Android), disposable gel pad consumables, and cloud-based clinician dashboards for monitoring and CMS-aligned billing.

Is NXTSTIM a public or private company?

NXTSTIM is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NXTSTIM founded?

NXTSTIM was founded in 2020. It employs 11 to 50 people.

Where is NXTSTIM based?

NXTSTIM is headquartered in San Diego, United States, in the North America region.

How does NXTSTIM make money?

Four revenue lines are on record. EcoAI Device Sales are the primary driver. The others are gel Pads (Consumables), remote Therapeutic Monitoring (RTM) Services and professional Services & Support.

Who are NXTSTIM's main competitors?

Broad incumbents on record are Boston Scientific, Abbott, Omron Healthcare, Medtronic and Axonics. Emerging players are SPR Therapeutics, Hinge Health and Cala Health. Direct peers are electroCore and NeuroMetrix.

Does NXTSTIM have an API?

No public API is recorded for NXTSTIM.

What industry is NXTSTIM in?

NXTSTIM's product category is Neuromodulation Pain Management Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLALABAK, Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales